CEO Eric Keller Discloses 7.07% Post-IPO Stake and 180-Day Lock-Up
RTSN sits 20% above its 52-week low of $9.66 on light trading volume (0.3× avg).
Summary
CEO Eric Keller disclosed a 7.07% post-IPO stake in Retension Pharmaceuticals and entered a 180-day lock-up agreement, restricting share sales until April 2026.
Key Events · Ownership and Investor Activity · RTSN
-
CEO Discloses 7.07% Post-IPO Stake
Eric Keller beneficially owns 598,598 shares (7.07% of class) after the IPO, reverse split, and preferred conversion.
-
180-Day Lock-Up Agreement
Keller is restricted from selling any shares until approximately April 2026 under a lock-up with Leerink Partners and Guggenheim Securities.
-
IPO Closing Option Grant
Keller received options to purchase 255,174 shares at $11.63 per share, vesting over four years.
-
Historical Pre-IPO Holdings
Prior to the IPO, Keller held common stock, Series A/B preferred, and options acquired between 2023 and 2025, all adjusted for the 1-for-6.21 reverse split.
Analysis · RTSN · Life Sciences
CEO Eric Keller's Schedule 13D reveals he now beneficially owns 598,598 shares, or 7.07% of Retension Pharmaceuticals, following the October 13 IPO. The filing also discloses a 180-day lock-up agreement with underwriters, preventing him from selling any shares until April 2026. This is a meaningful ownership disclosure from the company's chief executive and co-founder, providing clarity on his post-IPO stake and near-term selling restrictions.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RTSN was trading at $11.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.7M. The 52-week trading range was $9.66 to $12.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.